Cinctive Capital Management LP lifted its stake in argenx SE (NASDAQ:ARGX - Free Report) by 76.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,016 shares of the company's stock after purchasing an additional 2,598 shares during the quarter. Cinctive Capital Management LP's holdings in argenx were worth $3,700,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently modified their holdings of the stock. Steward Partners Investment Advisory LLC boosted its stake in argenx by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock valued at $234,000 after purchasing an additional 20 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company's stock valued at $220,000 after purchasing an additional 21 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of argenx by 38.2% during the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock valued at $47,000 after buying an additional 21 shares during the last quarter. Dynasty Wealth Management LLC increased its holdings in argenx by 3.4% in the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company's stock worth $416,000 after buying an additional 22 shares in the last quarter. Finally, Choreo LLC raised its position in argenx by 4.4% in the 4th quarter. Choreo LLC now owns 551 shares of the company's stock worth $342,000 after buying an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.
Analyst Ratings Changes
ARGX has been the topic of a number of recent analyst reports. Robert W. Baird raised their price target on shares of argenx from $650.00 to $680.00 and gave the company a "neutral" rating in a report on Tuesday, March 4th. Citigroup reaffirmed an "outperform" rating on shares of argenx in a research report on Friday, February 28th. William Blair reiterated an "outperform" rating on shares of argenx in a research note on Friday, February 28th. Deutsche Bank Aktiengesellschaft upgraded argenx from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. Finally, JMP Securities upped their price objective on argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a research report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $687.00.
Read Our Latest Research Report on ARGX
argenx Stock Performance
Shares of NASDAQ ARGX traded up $8.34 during midday trading on Tuesday, reaching $558.34. The stock had a trading volume of 198,434 shares, compared to its average volume of 298,547. The company has a market capitalization of $33.93 billion, a price-to-earnings ratio of -637.72 and a beta of 0.60. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21. The stock has a 50-day moving average of $619.46 and a 200-day moving average of $603.79.
argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. As a group, analysts forecast that argenx SE will post 3.13 EPS for the current fiscal year.
argenx Company Profile
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Stories
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
